Roche has bet big on immunotherapy medicines, including a range of treatments that harness a patient’s own immune system to target cancer. Roche has bet big on immunotherapy medicines, including a range of treatments that harness a patient’s own immune system to target cancer. The Basel-based drugmaker said patients who received Tecentriq, along with Roche’s older cancer drug Avastin and chemotherapy, showed a 38% reduced risk of their disease worsening, compared with patients who were given only Avastin and chemotherapy. Tecentriq is already approved for patients suffering from advanced bladder cancer but breaking into lung cancer would significantly widen the market for this drug. Roche is testing its immunotherapy drug Tecentriq for a wide range of cancers.

Source: Wall Street Journal December 07, 2017 06:00 UTC